This is an intermediate-size expanded access protocol to provide ONC201 to patients with H3 K27M-mutant and/or midline gliomas who cannot access ONC201 through clinical trials.
Main Inclusions/Exclusions:
- At least 14 to 90 days post frontline RT completion (depending on treatment arm)
- No previous exposure to Chimerix ONC201 or ONC206 (unless documented as a non-Chimerix source)
- Concurrent bevacizumab IS allowed
Indications:
- DIPG
- H3 K27M positive leptomeningeal disease
- H3 K27M positive primary spinal glioma
- Recurrent DMG with frontline RT completed by 19OCT2023
Contact: Neuro.Research@providence.org